368 related articles for article (PubMed ID: 19121670)
1. Burkholderia pseudomallei: animal models of infection.
Titball RW; Russell P; Cuccui J; Easton A; Haque A; Atkins T; Sarkar-Tyson M; Harley V; Wren B; Bancroft GJ
Trans R Soc Trop Med Hyg; 2008 Dec; 102 Suppl 1():S111-6. PubMed ID: 19121670
[TBL] [Abstract][Full Text] [Related]
2. Interaction between Burkholderia pseudomallei and the host immune response: sleeping with the enemy?
Gan YH
J Infect Dis; 2005 Nov; 192(10):1845-50. PubMed ID: 16235187
[TBL] [Abstract][Full Text] [Related]
3. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis.
Leakey AK; Ulett GC; Hirst RG
Microb Pathog; 1998 May; 24(5):269-75. PubMed ID: 9600859
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility to Burkholderia pseudomallei is associated with host immune responses involving tumor necrosis factor receptor-1 (TNFR1) and TNF receptor-2 (TNFR2).
Barnes JL; Williams NL; Ketheesan N
FEMS Immunol Med Microbiol; 2008 Apr; 52(3):379-88. PubMed ID: 18294191
[TBL] [Abstract][Full Text] [Related]
5. Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model.
Warawa J; Woods DE
FEMS Microbiol Lett; 2005 Jan; 242(1):101-8. PubMed ID: 15621426
[TBL] [Abstract][Full Text] [Related]
6. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
Feterl M; Govan B; Engler C; Norton R; Ketheesan N
Int J Antimicrob Agents; 2006 Nov; 28(5):460-4. PubMed ID: 17046208
[TBL] [Abstract][Full Text] [Related]
7. Dose-response model for Burkholderia pseudomallei (melioidosis).
Tamrakar SB; Haas CN
J Appl Microbiol; 2008 Nov; 105(5):1361-71. PubMed ID: 18778292
[TBL] [Abstract][Full Text] [Related]
8. [Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines].
Manzeniuk IN; Galina EA; Dorokhin VV; Kalachev IIa; Borzenkov VN; Svetoch EA
Antibiot Khimioter; 1999; 44(6):21-6. PubMed ID: 10422574
[TBL] [Abstract][Full Text] [Related]
9. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei.
Easton A; Haque A; Chu K; Lukaszewski R; Bancroft GJ
J Infect Dis; 2007 Jan; 195(1):99-107. PubMed ID: 17152013
[TBL] [Abstract][Full Text] [Related]
10. Virulence of Burkholderia pseudomallei does not correlate with biofilm formation.
Taweechaisupapong S; Kaewpa C; Arunyanart C; Kanla P; Homchampa P; Sirisinha S; Proungvitaya T; Wongratanacheewin S
Microb Pathog; 2005 Sep; 39(3):77-85. PubMed ID: 16084684
[TBL] [Abstract][Full Text] [Related]
11. Burkholderia pseudomallei animal and human isolates from Malaysia exhibit different phenotypic characteristics.
Lee SH; Chong CE; Lim BS; Chai SJ; Sam KK; Mohamed R; Nathan S
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):263-70. PubMed ID: 17350202
[TBL] [Abstract][Full Text] [Related]
12. The bacterial gene lfpA influences the potent induction of calcitonin receptor and osteoclast-related genes in Burkholderia pseudomallei-induced TRAP-positive multinucleated giant cells.
Boddey JA; Day CJ; Flegg CP; Ulrich RL; Stephens SR; Beacham IR; Morrison NA; Peak IR
Cell Microbiol; 2007 Feb; 9(2):514-31. PubMed ID: 16987331
[TBL] [Abstract][Full Text] [Related]
13. The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease?
Lazar Adler NR; Govan B; Cullinane M; Harper M; Adler B; Boyce JD
FEMS Microbiol Rev; 2009 Nov; 33(6):1079-99. PubMed ID: 19732156
[TBL] [Abstract][Full Text] [Related]
14. Multifactorial pathogenic mechanisms of Burkholderia pseudomallei as suggested from comparison with Burkholderia cepacia.
Wongwanich S; Chotanachan P; Kondo E; Kanai K
Southeast Asian J Trop Med Public Health; 1996 Mar; 27(1):111-8. PubMed ID: 9031412
[TBL] [Abstract][Full Text] [Related]
15. Heterologously type IV pilus expressed protein of Burkholderia pseudomallei is immunogenic but fails to induce protective immunity in mice.
Sangdee K; Waropastrakul S; Wongratanachewin S; Homchampa P
Southeast Asian J Trop Med Public Health; 2011 Sep; 42(5):1190-6. PubMed ID: 22299445
[TBL] [Abstract][Full Text] [Related]
16. Neutrophils are the predominant cell-type to associate with Burkholderia pseudomallei in a BALB/c mouse model of respiratory melioidosis.
Laws TR; Smither SJ; Lukaszewski RA; Atkins HS
Microb Pathog; 2011 Dec; 51(6):471-5. PubMed ID: 21798336
[TBL] [Abstract][Full Text] [Related]
17. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei.
Wiersinga WJ; van der Poll T; White NJ; Day NP; Peacock SJ
Nat Rev Microbiol; 2006 Apr; 4(4):272-82. PubMed ID: 16541135
[TBL] [Abstract][Full Text] [Related]
18. Advances and remaining uncertainties in the epidemiology of Burkholderia pseudomallei and melioidosis.
Currie BJ
Trans R Soc Trop Med Hyg; 2008 Mar; 102(3):225-7. PubMed ID: 18166205
[TBL] [Abstract][Full Text] [Related]
19. [Characterisation of Burkholderia pseudomallei Lethal Factor 1 (BLF1). A breakthrough against melioidosis].
Hautbergue G
Med Sci (Paris); 2012 Mar; 28(3):262-4. PubMed ID: 22480647
[No Abstract] [Full Text] [Related]
20. Progress toward development of vaccines against melioidosis: A review.
Sarkar-Tyson M; Titball RW
Clin Ther; 2010 Aug; 32(8):1437-45. PubMed ID: 20728758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
